Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Johnny Canuck who wrote (28289)	9/18/2000 1:03:06 PM
From: shasta23	Read Replies (1) \| Respond to of 67856

HI HARRY! You write that a buy signal was generated on the compx. Was wondering how you deal with this kind of situation where you have a buy signal but we just broke under the important 3800 support suggesting that we might test at least the bottom of the hammer of 8-11 which was 3687. Of course that's only 40 points away and we might reach that today the pace we're going. Do you wait to see if we reach that support area? Some of the prices are getting juicy here...RFMD in the 33s! Stefan

To: Johnny Canuck who wrote (28289)	9/19/2000 1:25:09 AM
From: Johnny Canuck	Read Replies (1) \| Respond to of 67856

Monday September 18, 7:57 pm Eastern Time Biotechs Continue September Selloff ``There's no negative news for the biotechs today. It's just a matter of biotechs taking their cue from the volatile Nasdaq even though biotechs and high-tech companies are different animals,'' said Matthew Geller, a drug analyst for CIBC World Markets. Geller said fundamentals for the biotech sector remain strong and added that positive data about some experimental drugs being developed by biotechnology firms are expected to be presented in coming months at scientific meetings. "Although the Nasdaq Biotech Index has been beaten up this month, it remains up over 37 percent for the year to date -- following a 101 percent advance in 1999." "Among Monday's losers were Protein Design Labs (NasdaqNM:PDLI - news), which shed $13-63/64, or 12.5 percent, to $97-41/64. The company is a leader in development of monoclonal antibodies, immune system proteins designed to precisely attack disease-associated proteins. Millennium Pharmaceuticals Inc. (NasdaqNM:MLNM - news) fell $13-7/8, or 10.3 percent, to 120-3/8, while genomics rival Human Genome Sciences Inc (NasdaqNM:HGSI - news) lost $13-1/2, or 8.6 percent, to 144. Gilead Sciences Inc (NasdaqNM:GILD - news), a Foster City, Calif.-based firm that specializes in antiviral drugs, fell $10-3/16, or almost 10 percent, to $93-1/4 despite release of positive study results for its experimental drug tenofovir against the HIV virus that causes AIDS. Meanwhile, large pharmaceutical firms -- with their strong balance sheets and established lines of profitable drugs -- were relatively steady as a sell-off in broad U.S. markets was sparked in part by earnings warnings from consumer products giant Gillette Co (NYSE:G - news) and industrial automation firm Rockwell International (NYSE:ROK - news)." "Pfizer Inc (NYSE:PFE - news), the world's largest drug company, rose 62 cents to $41-15/16, while Eli Lilly and Co. (NYSE:LLY - news) of Indianapolis rose $1-1/2 to $74-7/16. " biz.yahoo.com